These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 19004654

  • 1. Effects of short-term risedronate on bone resorption and patient satisfaction in postmenopausal osteoporosis patients.
    Fernandes CE, Zerbini C, Russo LA, Albernaz MA, Eis SR, Szejnfeld VL, Pompei LM.
    J Clin Densitom; 2009; 12(1):77-83. PubMed ID: 19004654
    [Abstract] [Full Text] [Related]

  • 2. Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.
    Ohtori S, Akazawa T, Murata Y, Kinoshita T, Yamashita M, Nakagawa K, Inoue G, Nakamura J, Orita S, Ochiai N, Kishida S, Takaso M, Eguchi Y, Yamauchi K, Suzuki M, Aoki Y, Takahashi K.
    J Clin Neurosci; 2010 Feb; 17(2):209-13. PubMed ID: 20044258
    [Abstract] [Full Text] [Related]

  • 3. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
    Bahlous A, Bouzid K, Sahli H, Sallami S, Abdelmoula J.
    Tunis Med; 2009 Jun; 87(6):380-1. PubMed ID: 19927782
    [Abstract] [Full Text] [Related]

  • 4. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD.
    J Bone Miner Res; 2003 Jun; 18(6):1051-6. PubMed ID: 12817758
    [Abstract] [Full Text] [Related]

  • 5. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
    Dane C, Dane B, Cetin A, Erginbas M.
    Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907
    [Abstract] [Full Text] [Related]

  • 6. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [Abstract] [Full Text] [Related]

  • 7. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
    Ste-Marie LG, Sod E, Johnson T, Chines A.
    Calcif Tissue Int; 2004 Dec; 75(6):469-76. PubMed ID: 15478000
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.
    Ilter E, Karalok H, Tufekci EC, Batur O.
    Climacteric; 2006 Apr; 9(2):129-34. PubMed ID: 16698659
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
    Palomba S, Manguso F, Orio F, Russo T, Oppedisano R, Sacchinelli A, Falbo A, Tolino A, Zullo F, Mastrantonio P.
    Menopause; 2008 Apr; 15(4 Pt 1):730-6. PubMed ID: 18698280
    [Abstract] [Full Text] [Related]

  • 10. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ, Im JA, Kim SH.
    Maturitas; 2008 Jun 20; 60(2):170-6. PubMed ID: 18572334
    [Abstract] [Full Text] [Related]

  • 11. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
    Hooper MJ, Ebeling PR, Roberts AP, Graham JJ, Nicholson GC, D'Emden M, Ernst TF, Wenderoth D.
    Climacteric; 2005 Sep 20; 8(3):251-62. PubMed ID: 16390757
    [Abstract] [Full Text] [Related]

  • 12. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Marques-Neto JF, Weryha G, Verbruggen N, Hustad CM, Mahlis EM, Melton ME.
    Int J Clin Pract; 2008 Apr 20; 62(4):575-84. PubMed ID: 18324951
    [Abstract] [Full Text] [Related]

  • 13. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis EP, Phipps R, Klaushofer K.
    Calcif Tissue Int; 2007 Aug 20; 81(2):73-80. PubMed ID: 17612779
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.
    J Assoc Physicians India; 2008 Jun 20; 56():418-24. PubMed ID: 18822620
    [Abstract] [Full Text] [Related]

  • 15. Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.
    Racewicz AJ, Schofield PJ, Cahall DL, Cline GA, Burgio DE.
    Curr Med Res Opin; 2007 Dec 20; 23(12):3079-89. PubMed ID: 17971285
    [Abstract] [Full Text] [Related]

  • 16. Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
    Zikan V, Stepan JJ.
    Bone; 2009 Apr 20; 44(4):634-8. PubMed ID: 19150421
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
    Ste-Marie LG, Brown JP, Beary JF, Matzkin E, Darbie LM, Burgio DE, Racewicz AJ.
    Clin Ther; 2009 Feb 20; 31(2):272-85. PubMed ID: 19302900
    [Abstract] [Full Text] [Related]

  • 18. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A.
    Horm Metab Res; 2008 Apr 20; 40(4):281-5. PubMed ID: 18275008
    [Abstract] [Full Text] [Related]

  • 19. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
    Durchschlag E, Paschalis EP, Zoehrer R, Roschger P, Fratzl P, Recker R, Phipps R, Klaushofer K.
    J Bone Miner Res; 2006 Oct 20; 21(10):1581-90. PubMed ID: 16995813
    [Abstract] [Full Text] [Related]

  • 20. The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.
    Karadag-Saygi E, Akyuz G, Bizargity P, Ay P.
    Gynecol Endocrinol; 2011 Dec 20; 27(12):1033-6. PubMed ID: 21627558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.